Apr. 29 at 9:49 AM
$TVGN vs. The Sector: Why this is the ultimate "Deep Value" AI play 💎(NFA). Look at the Market Cap arbitrage:
🔹 Recursion (
$RXRX):
$1.85B Cap
🔹 Schrödinger (
$SDGR):
$903M Cap
🔹 Absci (
$ABSI):
$604M Cap
🔹 Tevogen (
$TVGN): ONLY
$29M Cap! 🤯
Reality:
Tevogen is trading at a fraction of its peers despite having a 92% precision AI platform (PredicTcell™) and a vertically integrated model (CRO + Specialty Pharma + AI).
The Math:
If
$TVGN reaches just HALF the valuation of
$ABSI, the stock price would be over
$60.00. Analysts have a PT of
$100+ for a reason—the gap between current price and intrinsic value is massive (1,200%+ upside potential).
Why now?
1️⃣ AI platform training is complete and moving to commercial stage. 🤖
2️⃣ Strategic CRO acquisition closing by Q2 to bring
$50M+ revenue. 📈
3️⃣ Low volume accumulation suggests sellers are exhausted. 📉
The Nasdaq compliance issue is a temporary hurdle; the science and the revenue are the long-term drivers.
